Abraxane approved: The drug Abraxane has been recently approved by the FDA in the fight against late-stage pancreatic cancer as a part of patients’ chemotherapy regimens, WebProNews reports this Saturday, Sept. 7. The new drug by Celgene has already been approved to slow both breast cancer and non-small cell lung cancer, and the drug can now be used for those suffering from pancreatic cancer.
Having Abraxane approved by the FDA is welcome news for pancreatic cancer patients in particular who cannot have cancerous cells removed through surgery due to the late stages of the cancer, attests M.D. director of Hematology and Oncology products for the FDA Drug evaluation and Research Center.
“Patients with pancreatic cancer are often diagnosed after the cancer has advanced and cannot be surgically removed,” the FDA official noted. “In these situations, and in situations when the cancer has progressed following surgery, options like Abraxane can help prolong a patient’s life.”
Abraxane works with the new FDA approval to help extend patients’ lives by delaying overall tumor growth during the chemotherapy regimen. It is often sued in tandem with gemcitabine so that the pancreatic cancer does not spread to other parts of the human body quickly.
In a recent study, participants with late-stage pancreatic who received Abraxane as part of their chemotherapy regiments lived nearly 2 months longer than those who did not receive the drug. A considerable delay in cancer tumor growth and longer life spans (between one and three years) were also found.
"Those participants, who received Abraxane plus gemcitabine, experienced a delay in tumor growth. Abraxane caused an increase in one-year survival, 35 percent vs 22 percent (non-receivers) and also doubled the percentage of patients who survived for two years from the start of treatment, with 9 percent still alive compared with 4 percent for gemcitabine alone."
While a small step for some, concluded the report, having Abraxane approved is one victory for cancer survivors and continuing patients in the fight against cancer.